Genmab is launching a Phase 3 clinical trial investigating its bispecific antibody epcoritamab as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who fail to respond to, or are ineligible for, autologous stem cell transplant (ASCT). The open-label trial (NCT04628494) is expected to enroll up to 480 people whose tumors are positive for the CD20 protein, and whose prior treatments included at least one chemotherapy regimen containing an anti-CD20 antibody. Patients can…
You must be logged in to read/download the full post.
The post Phase 3 Study of Epcoritamab for Advanced DLBCL to Open in Europe, Australia appeared first on BioNewsFeeds.